Health Technology Santen Pharmaceutical Co., Ltd. Business Summary
Santen Pharmaceutical Co., Ltd engages in the manufacture and sale of pharmaceutical products and medical devices. It operates through the following segments: Pharmaceuticals and Others. The Pharmaceuticals segment includes prescription ophthalmic drugs, anti-rheumatic pharmaceuticals, and over-the-counter products. The Others segment offers medical equipment and devices. The company was founded by Kenkichi Tagushi in 1890 and is headquartered in Osaka, Japan.
Financial Highlights
Mar 2022
JPY USD Revenue 266,257M 2,369.41M Gross Profit 146,852M 1,306.83M Operating income 35,976M 320.14M Income before tax 37,220M 331.21M Net income 27,224M 242.26M EBITDA 53,031M 471.92M Diluted EPS 67.96 0.60 Dividends Per Share 32 0.28 Total Assets 459,976M 3,789.70M Total liabilities 123,134M 1,014.49M Total equity 337,488M 2,780.53M Operating cash flow 46,043M 409.73M Currency in JPY Currency in USD
Historical Data Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Revenue
224,942M
234,026M
241,555M
249,605M
266,257M
Gross Profit
129,618M
134,165M
134,703M
140,734M
146,852M
Operating income
38,637M
41,242M
40,125M
37,068M
35,976M
Income before tax
39,261M
43,117M
32,091M
12,046M
37,220M
Net income
35,247M
31,953M
23,616M
9,315M
27,224M
EBITDA
49,533M
52,211M
56,698M
54,990M
53,031M
Diluted EPS
86.42
78.43
59.00
23.25
67.96
Dividends Per Share
26
26
27
28
32
Total Assets
388,463M
391,186M
408,768M
405,285M
459,976M
Total liabilities
100,904M
98,614M
106,208M
95,641M
123,134M
Total equity
285,823M
290,900M
302,865M
310,181M
337,488M
Operating cash flow
42,843M
32,894M
39,947M
38,808M
46,043M
Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Revenue
2,029.56M
2,110.34M
2,221.69M
2,353.48M
2,369.41M
Gross Profit
1,169.49M
1,209.84M
1,238.92M
1,326.96M
1,306.83M
Operating income
348.60M
371.90M
369.04M
349.50M
320.14M
Income before tax
354.23M
388.81M
295.15M
113.57M
331.21M
Net income
318.02M
288.13M
217.20M
87.82M
242.26M
EBITDA
446.91M
470.81M
521.47M
518.49M
471.92M
Diluted EPS
0.77
0.70
0.54
0.21
0.60
Dividends Per Share
0.23
0.23
0.24
0.26
0.28
Total Assets
3,652.68M
3,534.22M
3,786.46M
3,667.73M
3,789.70M
Total liabilities
948.79M
890.94M
983.81M
865.52M
1,014.49M
Total equity
2,687.56M
2,628.17M
2,805.47M
2,807.06M
2,780.53M
Operating cash flow
386.55M
296.62M
367.41M
365.91M
409.73M
Valuation Measures
Mar 2022
PER 18.02 ROA 6.29% ROE 8.40% Operating margin 13.51% Profit margin 10.22%
Key executives
President & Chief Executive Officer:
Takeshi Ito
CFO, General Manager-Finance & Administration:
Kazuo Koshiji
Chief Information Officer, GM-Digital & IT:
Minori Hara
Chief Compliance Officer & Executive Officer:
Mika Masunari
Executive Officer:
Kenji Morishima Shareholders
Black Creek Investment Management, Inc. (5.3%)
Nomura Asset Management Co., Ltd. (5.1%)
Massachusetts Financial Services Co. (4.3%)
Sumitomo Mitsui Trust Asset Management Co., Ltd. (3.6%)
Mitsubishi UFJ Financial Group, Inc. (3.6%)
MFS International (UK) Ltd. (2.9%)
Nikko Asset Management Co., Ltd. (2.8%)
Nippon Life Insurance Co. (2.7%)
The Vanguard Group, Inc. (2.3%)
SPARX Asset Management Co., Ltd. (2.0%)
Contact Details Website: http://www.santen.co.jp Address:
Grand Front Osaka Tower A, 25/F,
4-20 Ofuka-cho,
Osaka,
530-8552,
Japan
Phone:
+81.6.7664.8621
Related Companies
Chongqing Santen Kerui Pharmaceutical Co. Ltd.
Santen China Investment Co. Ltd.
Santen LLC
Santen Pharmaceutical Performance Share Unit
Santen Pharmaceutical (Hong Kong) Ltd.
Phacor, Inc.
Santen Canada, Inc.
Santen Pharmaceutical Restricted Stock Compensation Plan
Santen Philippines, Inc.
Santen Pharma Malaysia Sdn. Bhd.
Santen (Thailand) Co. Ltd.
Santen SA
Santen Eye Care Co., Ltd.
Santen Business Services Co. Ltd.
Claire Co. Ltd.
Santen Pharmaceutical Spain SL
SantenPharma AB
Santen India Pvt Ltd.
Santen Pharmaceutical Korea Co. Ltd.
Santen Pharmaceutical Asia Pte Ltd.
Santen Pharmaceutical Sales & Marketing (Suzhou) Co., Ltd.
Taiwan Santen Pharmaceutical Co. Ltd.
Santen SAS
Santen Pharmaceutical Trust
Santen Pharmaceutical (China) Co. Ltd.
Santen Holdings U.S., Inc.
Santen Pharmaceutical Pension Fund
Santen GmbH
Santen Oy
Santen Holdings EU BV
Competitors
Nicox SA
EyePoint Pharmaceuticals, Inc.
HLB Therapeutics Co., Ltd.
CHO Pharma, Inc.
Satellos Bioscience Inc
PharmaEssentia Corp.
Copyright © 2023 FactSet Research Systems Inc. All rights reserved.
Last Updated on 27 Jan, 2023
Take your reading anywhere with offline reading functions Never miss a story with breaking news alerts Customize your reading experience
Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.
Celebrate our next chapter
Free access for everyone - Sep. 30
Find out more
By continuing to browse this website, you accept cookies which are used for several reasons such as personalizing content/ads and analyzing how this website is used. Please review our
Cookie Policy
to learn how you can update your cookie settings.
Accept & Continue
Close